Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus
NeOnc CEO Amir Heshmatpour bought another 37,000 NTHI shares on September 11 at a weighted-average price of $3.6654, roughly $135,620 of additional investment, per a September 14 Form 4. The piece recaps the $15 million financing announced September 9, priced at $4.20 per share plus five-year warrants for another 3.57 million shares at the same $4.20 exercise price, with proceeds earmarked for working capital, general corporate purposes, and redemption of Series A convertible preferred stock.
Key figures
- Offering Price
- 4.2
- Shares Offered
- 3570000
- Neo212 rp2d
- 610 mg
- Warrant term
- five years
- Neo100 6mo pfs
- 48.9%
- Warrant shares
- 3570000
- Neo100 patients
- 24
- Warrant exercise price
- 4.2
- Neo100 median os months
- 26.09
- Financing gross proceeds
- 15000000
- Insider shares purchased
- 37000
- Patent protection through
- 2038
- Insider purchase price avg
- 3.6654
- Insider purchase value usd
- 135620
- Neo100 pfs historical benchmark
- 20%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.